PDCD1 and melanoma: As well, there is clear evidence indicating the beneficial effects of administration of prolgolimab [146] and toripalimab [147], two other types of the anti-PD-1 monoclonal antibody, in melanoma patients [146] and also in patients with chemorefractory metastatic nasopharyngeal carcinoma (NPC) [147], respectively.